Top 3 Reasons Why Your Medical Device Needs a Clinical Trial
Regulations for research involving devices, in vitro diagnostics (IVDs), and digital therapeutics differ from those governing pharmaceutical development. While drugs
Regulations for research involving devices, in vitro diagnostics (IVDs), and digital therapeutics differ from those governing pharmaceutical development. While drugs
The Food and Drug Administration (FDA) recently released new guidance regarding cellular and gene therapy products, one of which may
Explore unique IRB considerations for first-in-human Phase I trials, from informed consent to participant protections and robust incentives.
Having a one in four chance of developing sickle cell disease (SCD) is uniquely, and overwhelmingly, familiar to the African
In an effort to accelerate the sharing of biomedical research results, the National Institutes of Health (NIH) issued its finalized
How do you know your experimental therapy is working? Sometimes, it can be as simple to determine as comparing drug
Discover the DSMB statistician’s critical role in safety monitoring, including SAPs, validated programming, and study design impact on analysis.
Metrics in general are one of the ways we can gauge how well a program or service delivers. In the
Navigating research compliance often means addressing unseen challenges. Explore strategies to identify blind spots and strengthen oversight frameworks.
Navigating research compliance often means addressing unseen challenges. Explore strategies to identify blind spots and strengthen oversight frameworks.
New privacy regulations seem to form every few months, especially with individual U.S. states adopting their own privacy regulations (e.g.,
In the past few years, new regulations and policies have been announced and implemented to address the challenges of conducting clinical trials involving multiple research sites. Chief among these requirements is the use of a designated sIRB for multisite research.